Skip to main content

Table 2 Demographic and clinical characteristics of men with PCa in the study region, metropolitan Melbourne and the rest of Victoria

From: Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia

  Study region, n (%) Metropolitan, n (%) Rest of Victoria, n (%) p
Included into the study 373 (5.2 %) 2,565 (35.6 %) 4,266 (59.2 %) 0.000
Age groups     0.000
 < 55 24 (6.4 %) 293 (11.4 %) 549 (12.9 %)  
 56–65 117 (31.4 %) 896 (34.9 %) 1,551 (36.4 %)  
 65–75 145 (38.9 %) 909 (35.4 %) 1,632 (38.3 %)  
 > 76 87 (23.3 %) 467 (18.2 %) 534 (12.5 %)  
 Age (mean, SD) 68.6 (8.9) 66.7 (9.3) 65.5 (8.8) 0.000
SEIFA     0.000
 Lowest 10 % (0–10 %) 70 (18.9 %) 93 (3.6 %) 217 (5.1 %)  
 Lowest 11–20 % 57 (15.4 %) 68 (2.7 %) 197 (4.6 %)  
 Lowest 21–30 % 9 (2.4 %) 77 (3.0 %) 232 (5.5 %)  
 Lowest 31–40 % 64 (17.3 %) 127 (5.0 %) 392 (9.2 %)  
 Lowest 41–50 % 113 (29.9 %) 160 (6.2 %) 293 (6.9 %)  
 Highest 51–60 % 32 (8.6 %) 119 (4.6 %) 291 (6.8 %)  
 Highest 61–70 % 18 (4.9 %) 208 (8.1 %) 496 (11.7 %)  
 Highest 71–80 % 8 (2.2 %) 325 (12.7 %) 546 (12.8 %)  
 Highest 81–90 % 1 (0.3 %) 747 (29.0 %) 907 (21.2 %)  
 Highest 10 % (91–100 %) 1 (0.3 %) 641 (25.0 %) 695 (16.2 %)  
Type of hospital     0.000
 Private 47 (12.6 %) 1,390 (54.2 %) 2,822 (66.2 %)  
 Public 326 (87.4 %) 1,175 (45.8 %) 1,444 (33.8 %)  
Method of diagnosis     0.000
 TRUS 285 (76.4 %) 2,081 (81.1 %) 3,919 (91.9 %)  
 TURP 77 (20.7 %) 416 (16.2 %) 291 (6.8 %)  
 Other 11 (2.9 %) 68 (2.7 %) 56 (1.3 %)  
PSA (ng/mL)     0.000
 < 4 45 (12.1 %) 427 (16.6 %) 688 (16.1 %)  
 4.01–10 176 (47.2 %) 1,337 (52.1 %) 2,408 (56.4 %)  
 10.01–20 74 (19.8 %) 395 (15.4 %) 679 (15.9 %)  
 > 20.01 72 (19.3 %) 301 (11.7 %) 426 (10.0 %)  
 Unknown 6 (1.6 %) 105 (4.1 %) 65 (1.5 %)  
Gleason score     0.000
 < 7 155 (41.6 %) 851 (33.2 %) 1,641 (38.5 %)  
 7 (3 + 4) 69 (18.6 %) 736 (28.7 %) 1,306 (30.6 %)  
 7 (4 + 3) 41 (10.9 %) 394 (15.4 %) 535 (12.6 %)  
 ≥ 8 103 (27.6 %) 577 (22.5 %) 782 (18.3 %)  
 Unknown 5 (1.3 %) 7 (0.3 %) 2 (0.0 %)  
NCCN risk group     0.000
 Low 73 (19.6 %) 478 (18.6 %) 911 (21.4 %)  
 Intermediate 113 (30.3 %) 1,064 (41.5 %) 1,887 (44.2 %)  
 High 97 (26.0 %) 616 (24.0 %) 867 (20.3 %)  
 Very high/Metastatic 44 (11.8 %) 133 (5.2 %) 245 (5.7 %)  
 Unknown 46 (12.3 %) 274 (10.7 %) 356 (8.3 %)